TNFR2 Overview
Molecule Name
Tumor necrosis factor receptor superfamily member 1B
Synonyms
TNFRSF1B,CD120b,TBPII,TNF-R-II,TNF-R75,TNFBR,TNFR1B,TNFR2,TNFR80,p75,p75TNFR
Drug Development Progress
Drugs in Clinical Trials8
Approved Drugs1
Highest Development StageApproved
Target Synonym
TNFR-II，TNFR80，TNF-RII，p80 TNF-alpha receptor，p75，Tumor necrosis factor receptor 2，Etanercept，TBP-2，Tumor necrosis factor receptor type II，TBPII，CD120b，TNF-R-II，CD120b Antigen，Tumor Necrosis Factor Beta Receptor，Soluble TNFR1B Variant 1，Tumor Necrosis Factor Binding Protein 2，TNFBR，TNF Receptor Superfamily Member 1B，TNFR2，P75 TNF Receptor，P75TNFR，TNFR1B，Tumor Necrosis Factor Receptor Superfamily， Member 1B，TNF-R75，TNF-R2
Background
TNFR2 (tumor necrosis factor receptor superfamily member 1B) is a receptor with high affinity for TNFSF2/TNF-alpha. It has a much lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. TNFR2 mediates most of the metabolic effects of TNF-alpha.
TNFR2 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| LBL-019 | LBL-019 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Neoplasms | Details |
| BI-1910 | BI-1910 | Phase 2 Clinical | Bioinvent International Ab | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| BITR-2101 | BITR-2101; BIR-2101; BITT2101; BITT-2101 | Phase 1 Clinical | Boston Immune Technologies & Therapeutics | Infections; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms | Details |
| TRB-061 | TRB-061 | Phase 1 Clinical | Trex Bio Inc | Colitis; Dermatitis; Dermatitis, Atopic | Details |
| NBL-020 | Phase 1 Clinical | Shanghai Xinshi Biological Medicine Co Ltd | Neoplasms; Solid tumours | Details | |
| BC-011 | BC-011 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours | Details |
| SIM1811-03 | SIM1811-03; SIM0235; SIM-235 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd | Lymphoma, T-Cell, Cutaneous; Neoplasms; Solid tumours | Details |
| Emunkitug | HFB-2003; HFB-200301 | Phase 1 Clinical | HiFiBiO Therapeutics | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Germinoma; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms; Sarcoma; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Testicular Neoplasms; Uterine Cervical Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological) | Approved | Hisun Biopharmaceutical Co Ltd | Mainland China | Spondylitis, Ankylosing; Psoriasis; Arthritis, Rheumatoid | Hisun Biopharmaceutical Co Ltd | 2015-04-09 | Arthritis, Rheumatoid; Psoriasis; Spondylitis, Ankylosing | Details |